First Patient Dosed in Phase 1b Trial of VYNE’s BET Inhibitor in Moderate-to-severe PsO
The first subject has been dosed in a Phase 1b trial evaluating VYNE Therapeutics Inc.’s VYN202 in moderate-to-severe plaque psoriasis. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases. The Phase 1b trial is a randomized, double-blind, placebo-controlled trial evaluating the safety, […]